| Market Cap | 363.73M | P/E | - | EPS this Y | 80.40% | Ern Qtrly Grth | - |
| Income | -565.3M | Forward P/E | -36.05 | EPS next Y | 5.70% | 50D Avg Chg | -9.00% |
| Sales | 1.19B | PEG | 0.17 | EPS past 5Y | 12.89% | 200D Avg Chg | -37.00% |
| Dividend | N/A | Price/Book | 0.30 | EPS next 5Y | -25.30% | 52W High Chg | -78.00% |
| Recommedations | 3.00 | Quick Ratio | 0.50 | Shares Outstanding | 52.40M | 52W Low Chg | 7.00% |
| Insider Own | 1.88% | ROA | -0.38% | Shares Float | 51.70M | Beta | 1.24 |
| Inst Own | 69.48% | ROE | -60.57% | Shares Shorted/Prior | 7.13M/5.70M | Price | 7.21 |
| Gross Margin | 32.44% | Profit Margin | -47.69% | Avg. Volume | 1,447,854 | Target Price | 5.00 |
| Oper. Margin | 13.25% | Earnings Date | Aug 6 | Volume | 1,511,597 | Change | -8.85% |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
| Benchmark | Buy | Apr 11, 24 |
| Benchmark | Buy | Mar 7, 24 |
| Benchmark | Hold | Aug 29, 23 |
| Benchmark | Buy | May 31, 23 |
| Benchmark | Buy | May 19, 23 |
| Benchmark | Buy | Apr 10, 23 |
| JP Morgan | Underweight | Mar 17, 23 |
| Benchmark | Hold | Nov 10, 22 |
| Chardan Capital | Buy | Nov 9, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zoon Kathryn C | Director Director | May 25 | Sell | 8.37 | 3,530 | 29,546 | 49,971 | 07/24/23 |
| Richard Ronald | Director Director | Nov 25 | Sell | 11.94 | 1,912 | 22,829 | 19,837 | 11/29/22 |
| Havey Adam | EVP, Business Operat.. EVP, Business Operations | Mar 03 | Option | 40.14 | 37,279 | 1,496,379 | 58,335 | 03/03/21 |
| Havey Adam | EVP, Business Operat.. EVP, Business Operations | Mar 03 | Sell | 99.32 | 37,279 | 3,702,550 | 38,190 | 03/03/21 |
| Kramer Robert | President and CEO President and CEO | Feb 09 | Option | 30.75 | 45,397 | 1,395,958 | 152,210 | 02/09/21 |
| Kramer Robert | President and CEO President and CEO | Feb 09 | Sell | 120.03 | 45,397 | 5,449,002 | 139,210 | 02/09/21 |
| Kramer Robert | President and CEO President and CEO | Jan 19 | Option | 25.62 | 19,026 | 487,446 | 158,236 | 01/19/21 |
| Kramer Robert | President and CEO President and CEO | Jan 19 | Sell | 106.01 | 19,026 | 2,016,946 | 139,210 | 01/19/21 |
| El-Hibri Fuad | Chairman Chairman | Nov 12 | Option | 26.45 | 39,391 | 1,041,892 | 1,143,379 | 11/12/20 |
| El-Hibri Fuad | Chairman Chairman | Nov 12 | Sell | 91.74 | 39,391 | 3,613,730 | 1,123,988 | 11/12/20 |
| El-Hibri Fuad | Chairman Chairman | Nov 04 | Option | 26.45 | 40,000 | 1,058,000 | 1,143,988 | 11/04/20 |
| El-Hibri Fuad | Chairman Chairman | Nov 04 | Sell | 90.59 | 40,000 | 3,623,600 | 1,123,988 | 11/04/20 |
| El-Hibri Fuad | Chairman Chairman | Sep 25 | Sell | 99.72 | 25,535 | 2,546,350 | 1,123,988 | 09/25/20 |
| El-Hibri Fuad | Chairman Chairman | Sep 18 | Sell | 101.58 | 40,000 | 4,063,200 | 1,149,523 | 09/18/20 |
| El-Hibri Fuad | Chairman Chairman | Sep 11 | Sell | 102.73 | 40,000 | 4,109,200 | 1,189,523 | 09/11/20 |
| SULLIVAN LOUIS W | Director Director | Sep 04 | Option | 20.08 | 7,893 | 158,491 | 50,655 | 09/04/20 |
| SULLIVAN LOUIS W | Director Director | Sep 04 | Sell | 111.22 | 28,418 | 3,160,650 | 42,762 | 09/04/20 |